AVEO Oncology Announces Webcast of Presentation at the 39th Annual J.P. Morgan Healthcare Conference
AVEO Oncology (Nasdaq: AVEO) announced that CEO Michael Bailey will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 5:20 p.m. ET. The presentation will be followed by a Q&A session with the management team. A live webcast of the event will be available on the company's website, with a replay archived for 30 days. AVEO is focused on developing oncology treatments, notably its lead candidate tivozanib, which is approved in the European Union for advanced renal cell carcinoma and is pending regulatory review in the U.S.
- AVEO's lead candidate tivozanib is approved in the EU for advanced renal cell carcinoma.
- Tivozanib is undergoing a regulatory submission in the U.S. for relapsed or refractory renal cell carcinoma.
- Promising early clinical data reported for ficlatuzumab in multiple cancer types.
- None.
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 5:20 p.m. Eastern Time. Following the presentation, Mr. Bailey will be joined by other members of AVEO’s management team for a question-and-answer session.
A live webcast of the presentation and question-and-answer session can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.
About AVEO Pharmaceuticals, Inc.
AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO’s strategy is to focus its resources toward development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO’s lead candidate, tivozanib, is approved as FOTIVDA® in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced renal cell carcinoma. Tivozanib is being studied in the TIVO-3 trial, which is supporting a regulatory submission of tivozanib in the U.S. seeking marketing approval as a treatment for relapsed or refractory renal cell carcinoma. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF mAb) in head and neck cancer, acute myeloid leukemia and pancreatic cancer and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab in head and neck cancer. AVEO’s earlier-stage pipeline includes several monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb), AV-380 (anti-GDF15 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion as a foundation for innovation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the section titled “Risk Factors” in AVEO’s most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its other filings with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005230/en/
FAQ
When is AVEO's presentation at the J.P. Morgan Healthcare Conference?
What is tivozanib and its status?
Where can I access the webcast of AVEO's presentation?
What cancers is ficlatuzumab being studied for?
How long will the webcast be available after the presentation?
